Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending July 8, 2018

PD-1 on peripheral Treg cells linked to prognosis in T cell non-Hodgkin lymphoma, Zuo M et al. Leukemia Research: 2018 (70); 56-61. https://doi.org/10.1016/j.leukres.2018.05.008

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

More must reads

Must reads for theWeek ending July 1, 2018

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

CAPTIVATE demonstrates encouraging results in CLL, Wierda WG et al. ASCO 2018, Abstract 7502.

ADC + BR improves response rate in diffuse large B-cell lymphoma, Sehn LH et al. EHA Congress, Abstract S802.

More must reads

Must reads for theWeek ending June 24, 2018

FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information ([email protected])

Toxicities more likely in older patients with CLL, NHL, Tallarico M et al. J Geriatr Oncol. 2018 Apr 16. pii: S1879-4068(18)30131-0.

More must reads

Must reads for theWeek ending June 17, 2018

Macrophage immune checkpoint inhibitor scores in NHL, Advani RH et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), abstract 7504.

Follicular lymphoma responds to no-chemo approach, Fowler NH et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7500.

More must reads

Must reads for theWeek ending June 3, 2018

Therapy toxicities higher with age in NHL, Tallarico M et al. J Geriatr Oncol. 2018 Apr 16. pii: S1879-4068(18)30131-0.

Waldenström’s macroglobulinemia responds to ibrutinib add-on therapy, Dimopoulos MA, et al. N Engl J Med. 2018 Jun 1. ASCO Abstract 8003.

Lymphoma risk linked to low exercise levels, Etter JL et al. Leuk Res. 2018 Mar 27;69:7-11.

NHL patients over age 65 have more toxicities to novel agents , Tallarico M et al. J Geriatr Oncol. 2018 Apr 16. pii: S1879-4068(18)30131-0

More must reads

Pages